CRISPR-Cas gene editing technologies offer revolutionary potential for treating genetic forms of atypical parkinsonism. While clinical application remains years away, understanding these approaches helps patients and families make informed decisions about research participation and future therapeutic options.
Gene editing uses molecular tools to directly modify DNA sequences, potentially correcting disease-causing mutations or modulating gene expression. For CBS and PSP, which involve tau pathology (4R-tauopathy), several genetic targets are relevant, including MAPT (tau gene), GBA (glucocerebrosidase), and GRN (progranulin).
The original CRISPR system uses Cas9 endonuclease to create double-strand breaks at targeted genomic locations.
Components:
- Guide RNA (gRNA): Directs Cas9 to specific genomic sequence
- Cas9 protein: Creates double-strand break
- Repair template: Provides corrected sequence for homology-directed repair
Limitations:
- Double-strand breaks can cause unintended edits
- Requires break and repair process
- Large size of Cas9 limits delivery options
Base editing allows precise single-nucleotide changes without double-strand breaks.
Types:
- Cytosine base editors (CBE): Convert C→T
- Adenine base editors (ABE): Convert A→G
- Glycosylase base editors: Expanded targeting
Advantages:
- No double-strand breaks
- Precise single-nucleotide changes
- Reduced off-target effects
Example Applications:
- Correcting MAPT P301L mutation
- Modifying GBA variants
- Creating protective APOE variants
Prime editing uses Cas9 fused to reverse transcriptase for precise insertions, deletions, and substitutions.
Advantages:
- All types of edits possible
- No double-strand breaks required
- Greater precision than standard CRISPR
Current Limitations:
- Larger construct size
- Lower efficiency
- Delivery challenges
Mutations:
- P301L, P301S: Cause familial PSP
- K257T, G389R: Cause CBD-like syndrome
Editing Strategies:
- Correct disease-causing mutations
- Disrupt cryptic splicing sites
- Reduce expression of mutant allele
Variants:
- N370S, L444P: Increase PD/CBS risk
- Null variants: Severe deficiency
Editing Strategies:
- Correct pathogenic variants
- Enhance GBA expression
- Reduce substrate accumulation
Mutations:
- Null mutations cause FTD
- May modify CBS/PSP risk
Editing Strategies:
- Restore expression
- Correct splice mutations
- Increase progranulin levels
Advantages:
- Long-term expression (years)
- Non-pathogenic
- Wide clinical use
Limitations:
- Small cargo capacity (~4.7 kb)
- Pre-existing immunity common
- Limited tissue targeting
For CNS Delivery:
- AAV9: Neuronal transduction
- AAV-PHP.B: Enhanced CNS penetration
- AAV2: Established safety profile
¶ Lipid Nanoparticles (LNPs)
Advantages:
- Larger cargo capacity
- No pre-existing immunity
- Repeat dosing possible
Current Status:
- COVID vaccines demonstrated safety
- CNS delivery being optimized
- mRNA delivery established
| Vector |
Cargo Capacity |
Duration |
Immunogenicity |
| AAV |
~4.7 kb |
Years |
Low-moderate |
| Lentivirus |
~8 kb |
Stable |
High |
| Adenovirus |
~36 kb |
Short-term |
High |
- In vitro models: iPSC-derived neurons from patient cells
- Animal models: Mouse models of tauopathy
- Proof-of-concept: Successful editing in mouse brain
- Clinical trials ongoing: Base editing for sickle cell, transthyretin amyloidosis
- CNS trials: Limited but expanding
- Timeline: CNS gene therapy 5-10 years away for CBS/PSP
- Brain delivery: Blood-brain barrier limits access
- Cell-type specificity: Targeting appropriate neurons
- Long-term safety: Unclear effects over decades
- Effect size: May require combination approaches
Somatic Editing:
- Only patient cells affected
- Changes not passed to offspring
- Currently preferred approach
- Lower ethical concern
Germline Editing:
- Affects embryos/germ cells
- Changes inherited by future generations
- Currently not clinically appropriate
- Higher ethical concern
Requirements:
- Understanding long-term uncertainties
- Risk of unintended edits
- Possibility of no direct benefit
- Alternative treatment options
¶ Access and Equity
Concerns:
- High cost may limit access
- Development priorities may favor common diseases
- Need for diverse population representation in trials
- Novel AAV capsids for CNS
- Targeted LNPs crossing BBB
- Exosome-based delivery
- Patient-specific guide RNAs
- Allele-specific editing
- Combination with other modalities
- FDA guidance for gene editing
- Accelerated approval pathways
- Real-world evidence integration